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Introduction
G protein–coupled receptors (GPCRs) are the largest family of 
signaling receptors expressed in mammalian cells and mediate 
vast physiological responses. The temporal and spatial fidelity 
of GPCR signaling is critical for appropriate cellular responses. 
Moreover, dysregulated GPCR signaling has been implicated in 
numerous human diseases including neurodegeneration and 
cancer progression (Hanyaloglu and von Zastrow, 2008; Marchese 
et al., 2008). In addition to desensitization, GPCR trafficking is 
important for the precise regulation of signaling responses. This 
is particularly true for protease-activated receptor 1 (PAR1), a 
GPCR for thrombin (Coughlin, 2000; Arora et al., 2007). Throm-
bin cleaves the N terminus of PAR1, unmasking a new N-terminal 
domain, which functions as a tethered ligand that activates 
the receptor through intramolecular binding (Vu et al., 1991). 
Once activated, PAR1 is internalized and sorted directly to ly-
sosomes and degraded, a process important for termination 
of G protein signaling (Trejo et al., 1998; Booden et al., 2004). 
The mechanism by which activated PAR1 is trafficked to lyso-
somes is not known.
The sorting of transmembrane proteins such as EGF re-
ceptor (EGFR) from the plasma membrane to lysosomes has 
been extensively studied and is mediated by the endosomal 
sorting complex required for transport (ESCRT). The ESCRT 
machinery is comprised of distinct complexes that function co-
ordinately to sort ubiquitinated receptors to intraluminal vesicles 
(ILVs) of multivesicular bodies (MVBs; Hurley and Hanson, 
2010). Hepatocyte growth factor–regulated tyrosine kinase sub-
strate (HRS), a component of ESCRT-0, recruits ubiquitinated 
receptors and Tsg101, a ubiquitin-binding subunit of ESCRT-I 
(Lu et al., 2003). ESCRT-I and -II function in receptor sorting to 
The sorting of signaling receptors to lysosomes is an essential regulatory process in mammalian cells. During degradation, receptors are modified with 
ubiquitin and sorted by endosomal sorting complex re-
quired for transport (ESCRT)–0, –I, –II, and –III complexes 
into intraluminal vesicles (ILVs) of multivesicular bodies 
(MVBs). However, it remains unclear whether a single uni-
versal mechanism mediates MVB sorting of all receptors. 
We previously showed that protease-activated receptor 1 
(PAR1), a G protein–coupled receptor (GPCR) for throm-
bin, is internalized after activation and sorted to lysosomes 
independent of ubiquitination and the ubiquitin-binding 
ESCRT components hepatocyte growth factor–regulated 
tyrosine kinase substrate and Tsg101. In this paper, 
we report that PAR1 sorted to ILVs of MVBs through an 
ESCRT-III–dependent pathway independent of ubiquitina-
tion. We further demonstrate that ALIX, a charged MVB 
protein 4–ESCRT-III interacting protein, bound to a YPX3L 
motif of PAR1 via its central V domain to mediate lysosomal 
degradation. This study reveals a novel MVB/lysosomal 
sorting pathway for signaling receptors that bypasses 
the requirement for ubiquitination and ubiquitin-binding 
ESCRTs and may be applicable to a subset of GPCRs con-
taining YPXnL motifs.
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by examining its colocalization with the lysosomal-associated 
membrane protein 1 (LAMP1) in HeLa cells using immuno-
fluorescence confocal microscopy. In the absence of agonist 
stimulation, PAR1 WT and 0K mutant cycle constitutively 
between the plasma membrane and early endosomes (Paing et al., 
2006; Wolfe et al., 2007). Consistent with these studies, we 
found that PAR1 WT and 0K mutant localized predominantly 
to the cell surface and early endosomes and showed no signifi-
cant colocalization with LAMP1 under control conditions 
(Figs. 1 A and S1 A). However, after 60 min of agonist stimu-
lation, PAR1 WT colocalized extensively with LAMP1-positive 
vesicles (Fig. 1 A), as previously reported (Trejo et al., 2000). 
Activation of PAR1 0K mutant with agonist for 60 min also 
resulted in substantial receptor colocalization with LAMP1 
(Fig. 1 A). The colocalization of activated PAR1 WT and 0K 
mutant with LAMP1 was verified by determining Pearson’s 
correlation coefficient for PAR1 WT (r = 0.30 ± 0.05; n = 6) 
and 0K mutant (r = 0.30 ± 0.08; n = 6). Thus, after activation, 
PAR1 0K mutant is efficiently sorted to lysosomes like WT 
ILVs and ILV formation (Wollert and Hurley, 2010). ESCRT-III 
polymerizes on endosomal membranes and is the main driver 
of ILV scission. The AAA-ATPase vacuolar protein sorting 4 
(Vps4) disassembles and recycles ESCRT-III components and 
is essential for ESCRT function. In addition to receptor sorting 
at the MVB, ESCRT mediates viral budding and cytokinesis 
through processes that require ESCRT-I and -III and ALIX, 
an ESCRT-III–interacting protein, but not ESCRT-0 or -II (Strack 
et al., 2003; Carlton et al., 2008). Whether there are differences 
in ESCRT requirements for the sorting of signaling receptors 
at the MVB in mammalian cells remains unclear.
Most GPCRs require posttranslational modification with 
ubiquitin and ESCRTs for sorting from endosomes to lyso-
somes. The chemokine receptor CXCR4 is ubiquitinated after 
activation and sorted from endosomes to lysosomes through a 
pathway that requires HRS and Vps4 (Marchese et al., 2003). 
PAR2, a GPCR related to PAR1, also undergoes agonist-induced 
ubiquitination and is sorted to lysosomes through an HRS-
dependent pathway (Hasdemir et al., 2007). However, not all 
GPCRs require direct ubiquitination for MVB sorting and lysoso-
mal degradation, as exemplified by the -opioid receptor (DOR). 
A ubiquitination-deficient DOR mutant is efficiently sorted to 
ILVs of MVBs similar to wild-type (WT) receptor (Henry et al., 
2011). However, degradation of DOR requires HRS and Vps4 
but not Tsg101 (Hislop et al., 2004), indicating that receptor 
sorting can occur independent of ubiquitination and requires 
some but not all components of the ubiquitin-binding ESCRT 
machinery. Thus, it remains to be determined whether a signal-
ing receptor can bypass the requirement for both ubiquitination 
and ubiquitin-binding components of the ESCRT machinery 
and sort to MVBs/lysosomes.
We previously showed that activated PAR1 is efficiently 
sorted from endosomes to lysosomes and degraded independent 
of ubiquitination (Wolfe et al., 2007). In contrast to DOR, how-
ever, neither HRS nor Tsg101 is essential for lysosomal degra-
dation of PAR1 (Gullapalli et al., 2006). Thus, it is not known 
whether activated PAR1 ultimately sorts to ILVs of MVBs and 
requires any components of the ESCRT machinery for lyso-
somal degradation. Here, we report that activated PAR1 sorts 
to ILVs of MVBs through a pathway that requires ALIX and 
ESCRT-III function but not receptor ubiquitination. Moreover, 
our findings indicate that ALIX binds to a YPX3L motif of PAR1 
and recruits ESCRT-III to mediate MVB/lysosomal sorting.
Results
Activated PAR1 sorts to ILVs of MVBs 
independent of ubiquitination
Activated PAR1 WT is internalized, sorted efficiently to lyso-
somes, and rapidly degraded with a half-life of 30 min (Trejo 
and Coughlin, 1999). In previous work, we showed that a PAR1 
lysine-less 0K mutant defective in ubiquitination is degraded 
comparably with WT receptor after activation (Wolfe et al., 
2007), suggesting that PAR1 degradation occurs independent 
of ubiquitination. To investigate the mechanism of ubiquitin-
independent degradation of PAR1, we first determined whether 
agonist promoted lysosomal sorting of the PAR1 0K mutant 
Figure 1. PAR1 is sorted to MVBs independent of ubiquitination. (A) HeLa 
cells expressing FLAG-PAR1 WT or 0K mutant were pretreated with 0.2 mM 
leupeptin. Cells were then incubated without (Control) or with 100 µM 
SFLLRN (SF) for 60 min at 37°C, fixed, permeabilized, and incubated 
with anti-FLAG and -LAMP1 antibodies. Immunolabeled cells were pro-
cessed and imaged by confocal microscopy. The colocalization of PAR1 
and LAMP1 is shown in yellow in the merged image and is representative 
of many cells examined in three independent experiments. Insets show 
magnifications of boxed areas. Bars, 10 µm. The data (mean ± SD) repre-
sent Pearson’s correlation coefficients that were calculated for PAR1 and 
LAMP1 colocalization for control versus agonist-stimulated conditions and 
were significant, as determined by Student’s t test (***, P < 0.001; n = 6). 
(B and C) HeLa cells expressing FLAG-PAR1 WT or 0K mutant were pre-
labeled with anti-FLAG antibody for 1 h at 4°C and then stimulated with 
100 µM SFLLRN for 20 min at 37°C. Cells were fixed and processed for 
immuno-EM. Dual-labeled ultrathin sections revealed that PAR1 WT and 0K 
mutant detected with 12-nm gold-conjugated secondary antibody (black 
arrows) sorted to ILVs present in CD63-positive MVBs, which was detected 
with 6-nm gold-labeled secondary antibody (white arrows). Bar, 100 nm.
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antibodies commercially available, we were unable to exam-
ine endogenous CHMP4C protein expression in siRNA-trans-
fected cells.
To assess the function of CHMP4 in PAR1 degradation, 
HeLa cells expressing FLAG-PAR1 were transfected with ei-
ther nonspecific or CHMP4-specific siRNAs. Cells were then 
incubated with agonist for 60 min, and PAR1 degradation was 
assessed. In nonspecific siRNA-transfected cells, an 50% de-
crease in the amount of PAR1 protein was detected after 60 min 
of agonist incubation compared with unstimulated control cells 
(Fig. 2 B, lanes 1 and 2). The extent of PAR1 degradation was 
similar in nonspecific and CHMP4A siRNA–transfected cells 
after agonist stimulation, suggesting that CHMP4A is not es-
sential for PAR1 degradation (Fig. 2 B, lanes 1–4). In contrast, 
agonist-induced degradation of PAR1 was significantly inhib-
ited in cells transfected with either CHMP4B or CHMP4C 
siRNA SMARTpools (Fig. 2 B, lanes 5–8), indicating that both 
CHMP4B and C isoforms are necessary for PAR1 degradation. 
Cells transfected with single siRNAs targeting CHMP4B resulted 
in loss of endogenous CHMP4B expression and also blocked 
agonist-promoted PAR1 degradation (Fig. S2). These results 
receptor, suggesting that ubiquitination is not essential for 
PAR1 lysosomal sorting.
A critical step in lysosomal sorting and degradation of 
most proteins in mammalian cells requires incorporation into 
ILVs of the MVB. To determine whether PAR1 directly enters 
ILVs of MVBs independent of receptor ubiquitination, we per-
formed immuno-EM on ultrathin cryosections of HeLa cells 
expressing PAR1 WT or ubiquitin-deficient 0K mutant. To ex-
amine endocytic sorting of the cell surface cohort of PAR1 WT 
and 0K mutant after agonist activation, receptors were prela-
beled with anti-FLAG antibody at 4°C and then treated with 
agonist for 20 min. After agonist stimulation, activated PAR1 WT 
(12-nm gold particles) sorted to an endosomal compartment 
that colabeled with the late endosome/MVB marker CD63 (6-nm 
gold particles; Fig. 1 B), suggesting that activated PAR1 traffics 
to MVBs. Remarkably, the ubiquitination-deficient PAR1 0K 
mutant also localized to ILVs of CD63-positive MVBs after ag-
onist activation (Fig. 1 C), indicating that PAR1 traffics to ILVs 
of MVBs independent of receptor ubiquitination. To ensure that 
antibody prelabeling did not alter the internalization and sorting 
of PAR1, we examined the colocalization of PAR1 WT and 0K 
mutant with LAMP1 by immunofluorescence confocal micros-
copy in parallel. As expected, PAR1 WT and 0K mutant local-
ized to the cell surface and early endosomes and did not 
colocalize with LAMP1 after incubation for 20 min in the ab-
sence of agonist (Fig. S1, B and C). In contrast, however, stimu-
lation of PAR1 WT and 0K mutant with agonist for 20 min 
caused significant colocalization with LAMP1 (Fig. S1, B and C), 
consistent with that observed in cells not prelabeled with anti-
body (Fig. 1 A). Together, these data demonstrate that ubiqui-
tination of activated PAR1 is not required for entry into ILVs 
of MVBs and suggest that a novel pathway exists for the sorting 
of nonubiquitinated receptors to the lysosome.
ESCRT-III and Vps4 mediate PAR1 
lysosomal degradation
To define the ubiquitin-independent lysosomal degradation 
pathway of PAR1, we examined the function of ESCRT-III 
components, which do not contain any known ubiquitin-binding 
domains (Hurley and Hanson, 2010). Charged MVB protein 4 
(CHMP4) is the most abundant subunit of ESCRT-III, which 
serves as the critical mediator of ILV scission, and exists as 
three isoforms: CHMP4A, B, and C (Wollert and Hurley, 
2010). We first determined the expression of CHMP4 isoforms 
in HeLa cells using RT-PCR and CHMP4 isoform–specific 
primers (Fig. 2 A, lanes 6–8). RT-PCR assay of HeLa cell RNA 
revealed the presence of all three isoforms, including CHMP4A, 
B, and C (Fig. 2 A, lanes 1 and 2). To assess CHMP4 function 
in PAR1 degradation, siRNAs that specifically target each of the 
three CHMP4 isoforms expressed in HeLa cells were used. 
HeLa cells transfected with CHMP4 isoform–specific siRNA 
SMARTpools exhibited a substantial decrease in CHMP4A, B, 
and C mRNA transcripts, as revealed by RT-PCR (Fig. 2 A, 
lanes 3–5). Consistent with diminished mRNA transcripts, 
CHMP4-specific siRNAs also caused significant depletion of 
endogenous CHMP4A and CHMP4B protein, as detected by 
immunoblotting (Fig. 2 B). Because there are no anti-CHMP4C 
Figure 2. CHMP4 mediates PAR1 lysosomal degradation. (A) RT-PCR as-
says of HeLa RNA using CHMP4A, B, or C isoform–specific primers. No 
RT is indicated (). RNA isolated from HeLa cells transfected with 100 nM 
CHMP4A-, B-, or C-specific siRNAs was subject to RT-PCR. As a control, 
1 ng CHMP4A, B, and C cDNA plasmids was amplified by RT-PCR in par-
allel. The asterisk indicates a nonspecific band. (B) HeLa cells expressing 
FLAG-PAR1 were transfected with 100 nM of nonspecific (ns) or CHMP4 
isoform–specific siRNAs and stimulated with 100 µM SFLLRN for 60 min at 
37°C, and PAR1 degradation was assessed. Cell lysates were immuno-
blotted (IB) with anti-CHMP4A, -CHMP4B, and -actin antibodies. The data 
(mean ± SD) are expressed as the fraction of PAR1 remaining compared 
with untreated control (Ctrl). The amount of PAR1 detected in CHMP4B and 
CHMP4C siRNA–treated cells was significantly different from nonspecific 
siRNA-treated cells, determined by a two-way analysis of variance (*, P < 
0.05; ***, P < 0.001; n = 3).
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the time course for agonist-induced PAR1 localization to ILVs 
of MVBs and suggest that CHMP4B is a component of the 
ESCRT-III complex that binds to activated PAR1. Next, we 
examined PAR1 interaction with CHMP4C in HeLa cells trans-
fected with an HA-tagged CHMP4C, as CHMP4C antibodies are 
not available. HeLa cells coexpressing FLAG-PAR1 and 
HA-CHMP4C were incubated with agonist for various times, 
PAR1 was immunoprecipitated, and CHMP4C association 
was assessed. In unstimulated control cells, CHMP4C failed 
to interact with PAR1 (Fig. 4 B). However, after activation of 
PAR1 for 10 min, a marked increase in CHMP4C association 
with PAR1 was detected (Fig. 4 B). Next, we examined 
whether the ubiquitin-deficient PAR1 0K mutant interacted 
suggest that CHMP4 mediates agonist-induced PAR1 lyso-
somal degradation.
The AAA-ATPase Vps4 catalyzes ESCRT-III disassem-
bly and recycling and is critical for ESCRT function (Hurley 
and Hanson, 2010). To examine the role of Vps4 in agonist-
induced PAR1 degradation, we used a catalytically inactive 
Vps4 E228Q variant, which functions as a dominant-negative 
mutant (Babst et al., 1998; Bishop and Woodman, 2000). 
HeLa cells coexpressing PAR1 and either Vps4 WT or E228Q 
mutant fused to GFP were incubated with agonist, and recep-
tor degradation was assessed. Interestingly, agonist-promoted 
PAR1 degradation was significantly inhibited in cells co-
expressing Vps4 E228Q mutant compared with Vps4 WT– 
expressing cells (Fig. 3 A), indicating that Vps4 mediates 
MVB sorting of PAR1. Agonist-promoted PAR2 degradation 
was similarly inhibited in Vps4 E228Q mutant–expressing 
cells compared with control cells expressing WT Vps4 (Fig. 3 B). 
PAR1 and PAR2 degradation induced by agonist was also in-
hibited in cells transfected with siRNAs targeting both Vps4A 
and B isoforms (Fig. S3, A and B). These results suggest that 
Vps4 is required for both ubiquitin- and nonubiquitin-mediated 
lysosomal sorting of GPCRs.
Next, we evaluated Vps4 function in MVB/lysosomal 
sorting of activated PAR1 and PAR2 by immunofluorescence 
confocal microscopy. Cells coexpressing FLAG-PAR1 or 
FLAG-PAR2 and either Vps4 WT or E228Q mutant fused to 
GFP were incubated with anti-FLAG antibody at 4°C to ensure 
only the cell surface receptors would be labeled and then stim-
ulated with agonist. In the absence of agonist, PAR1 and 
PAR2 localized predominantly to the cell surface, whereas 
agonist-stimulated PAR1 and PAR2 redistributed from the 
cell surface to endosomes (Fig. 3, C and D). As expected, co-
expression of Vps4 E228Q mutant resulted in accumulation of 
internalized PAR2 in enlarged vesicles, defined as a class E 
phenotype that results from disruption of ESCRT-III recycling 
(Fig. 3 D; Babst et al., 1998; Bishop and Woodman, 2000). In 
contrast, PAR1-containing endosomes were unperturbed in 
Vps4 E228Q mutant–expressing cells and appeared similar to 
those in adjacent untransfected cells and cells expressing Vps4 
WT (Fig. 3 C). Aberrant localization of CD63 observed in 
cells coexpressing PAR1 and Vps4 E228Q mutant indicates 
disruption of the MVB compartment (Fig. 3 C). Thus, in con-
trast to ubiquitinated cargo, PAR1 fails to accumulate at the 
MVB when the pathway is disrupted, suggesting that MVB 
sorting of PAR1 is distinctly regulated.
To confirm ESCRT-III function in PAR1 lysosomal deg-
radation, we examined whether activated PAR1 forms a com-
plex with CHMP4. We first assessed the coassociation of 
endogenous CHMP4B with activated PAR1 in HeLa cells by 
coimmunoprecipitation. HeLa cells expressing FLAG-PAR1 
WT were incubated with agonist for various times, PAR1 was 
immunoprecipitated, and association of CHMP4B was exam-
ined. In the absence of agonist, PAR1 and CHMP4B inter-
action was undetectable (Fig. 4 A). However, an interaction 
between PAR1 and endogenous CHMP4B was detected after 
10 min of agonist stimulation, and the proteins remained asso-
ciated for 20 min (Fig. 4 A). These findings coincide with 
Figure 3. PAR1 does not accumulate in Vps4 E228Q–positive endo-
somes. (A and B) HeLa cells expressing FLAG-PAR1 or FLAG-PAR2 were 
transfected with either Vps4-GFP or Vps4 E228Q–GFP. Cells were stimu-
lated with 100 µM SFLLRN or 100 µM SLIGKV, as indicated, and lysed, 
and equivalent amounts of lysates were immunoprecipitated (IP), and 
PAR degradation was assessed by immunoblotting (IB). Cell lysates were 
immunoblotted with anti-GFP and -actin antibodies. The data (mean ± SD) are 
expressed as the fraction of PAR1 remaining compared with untreated 
control (Ctrl) and were analyzed by a two-way analysis of variance 
(**, P < 0.01; ***, P < 0.001; n = 3). (C and D) HeLa cells express-
ing FLAG-PAR1 or FLAG-PAR2 and either GFP-tagged Vps4 or E228Q 
mutant were prelabeled with anti-FLAG antibody for 1 h at 4°C, washed, 
and stimulated with 100 µM SFLLRN or 100 µM SLIGKV at 37°C, as 
indicated. Cells were fixed, permeabilized, and immunostained for PAR1 
and CD63. Cells coexpressing PAR1 or PAR2 and either Vps4 WT or 
E228Q mutant are indicated by the arrowheads. The insets are magnifi-
cations of the boxed areas. Bars, 10 µm.
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endogenous ALIX association (Fig. 5 B), suggesting that 
ubiquitination is not required for ALIX interaction with acti-
vated PAR1.
ALIX has been shown to link certain viral proteins to the 
ESCRT-III complex, a process important for viral budding (Usami 
et al., 2007). Therefore, we examined whether ALIX was re-
quired for agonist-induced PAR1 interaction with CHMP4. 
HeLa cells coexpressing FLAG-PAR1 and HA-CHMP4B 
transfected with nonspecific or ALIX-specific siRNAs were 
treated with agonist, PAR1 was immunoprecipitated, and CHMP4 
association was assessed. In nonspecific siRNA control cells, a 
10-min incubation with agonist resulted in robust PAR1 associ-
ation with CHMP4B (Fig. 5 C, lanes 1–4). In striking contrast, 
activated PAR1 interaction with CHMP4B was virtually ab-
lated in ALIX-deficient cells (Fig. 5 C, lanes 5–8). These find-
ings suggest that ALIX links PAR1 to the ESCRT-III machinery 
to facilitate lysosomal sorting.
Next, we assessed ALIX function in agonist-induced 
PAR1 lysosomal degradation. HeLa cells expressing FLAG-
PAR1 were transfected with ALIX-specific siRNAs and stim-
ulated with agonist for various times, and PAR1 degradation 
was examined. In ALIX-deficient cells, agonist-promoted 
degradation of PAR1 was significantly inhibited compared 
with the extent of PAR1 degradation observed after 60 min of 
agonist stimulation in siRNA-treated control cells (Fig. 6 A). 
However, internalization of activated PAR1 occurred normally 
in ALIX-deficient cells (Fig. S4 D), indicating that ALIX me-
diates PAR1 sorting to a lysosomal degradative pathway after 
internalization. Depletion of endogenous ALIX expression 
also caused a significant defect in agonist-promoted degra-
dation of endogenous PAR1-expressed human endothelial 
cells (Fig. 6 B). Moreover, agonist-induced degradation of 
ubiquitination-deficient PAR1 0K mutant was also impaired 
in ALIX-deficient cells, whereas activated PAR2 degradation 
with CHMP4 proteins. Similar to WT PAR1, both CHMP4B 
and CHMP4C coimmunoprecipitated with activated PAR1 0K 
mutant after 10 min of agonist stimulation (Fig. 4 C), indicat-
ing that CHMP4B and CHMP4C are components of the PAR1 
ubiquitin–independent sorting complex. In contrast, FLAG-
tagged 2-adrenergic receptor (2AR), a classical GPCR, failed 
to coimmunoprecipitate with HA-CHMP4B or HA-CHMP4C 
in PAR1-expressing cells stimulated with the PAR1-specific 
agonist for 10 min (Fig. 4 D). Together, these findings demon-
strate that ESCRT-III binds specifically to activated PAR1 
and regulates MVB/lysosomal degradation.
The ESCRT-III–associated protein ALIX  
is required for PAR1 degradation
To further define the PAR1 ubiquitin–independent lysosomal 
sorting pathway, we investigated the function of ALIX, a CHMP4-
interacting protein that recruits ESCRT-III to membranes (Fisher 
et al., 2007). We first examined whether PAR1 interacted with 
endogenous ALIX in HeLa cells. Cells expressing FLAG-PAR1 
were stimulated with agonist for various times, PAR1 was im-
munoprecipitated, and association of endogenous ALIX was 
assessed. In cells treated with agonist for 10 min, PAR1 associa-
tion with endogenous ALIX was markedly increased compared 
with untreated control cells (Fig. 5 A, lanes 1 and 2), whereas 
PAR1 and ALIX interaction was diminished after 20 min of 
agonist exposure (Fig. 5 A, lanes 1–3). In contrast, PAR2 and 
ALIX interaction was negligible in control and agonist-treated 
cells (Fig. 5 A, lanes 4 and 5). PAR1 also associated with 
HA-ALIX in an agonist-dependent manner (Fig. S4 A), whereas 
HA-ALIX failed to bind to 2AR in cells treated with PAR1-
specific agonist (Fig. S4 B) or to activated PAR2 (Fig. S4 C). 
Next, we examined the association of endogenous ALIX with 
ubiquitination-deficient PAR1 in HeLa cells. In contrast to control 
cells, activation of the PAR1 0K mutant for 10 min resulted in 
Figure 4. Activated PAR1 coassociates with 
CHMP4. (A) HeLa cells expressing FLAG-PAR1 
were stimulated with 100 µM SFLLRN for 
various times at 37°C. Equivalent amounts 
of cell lysates were immunoprecipitated (IP) 
with anti-PAR1 antibody, and the presence of 
endogenous CHMP4B was determined by 
immunoblotting (IB). Cell lysates were immuno-
blotted with anti-CHMP4B and -actin antibodies. 
(B and C) HeLa cells expressing FLAG-PAR1 
(B) or FLAG-PAR1 0K (C) and coexpressing 
HA-CHMP4C or HA-CHMP4B were stimulated 
with 100 µM SFLLRN at 37°C, as indicated. 
Equivalent amounts of cell lysates were immuno-
precipitated with M2 anti-FLAG antibody or 
IgG control, and the presence of FLAG-PAR1 or 
PAR1 0K and associated HA-CHMP4 was de-
termined by immunoblotting. Cell lysates were 
immunoblotted with anti-HA and -actin anti-
bodies. (D) PAR1-expressing HeLa cells were 
cotransfected with FLAG-tagged 2-adrenergic 
receptor (2AR) and either HA-CHMP4B or 
HA-CHMP4C and stimulated with 100 µM 
SFLLRN at 37°C for 10 min. FLAG-2AR was 
immunoprecipitated with anti-FLAG antibody, 
and immunoprecipitates were analyzed by 
immunoblotting using anti-HA antibodies. Cell 
lysates were immunoblotted with anti-HA 
and -actin antibodies as controls.
JCB • VOLUME 197 • NUMBER 3 • 2012 412
ALIX binds to a highly conserved YPXnL 
motif in PAR1 via its central V domain
ALIX contains an N-terminal Bro1 domain, a central V domain, 
and C-terminal proline-rich region. ALIX binds to YPXnL motifs 
present in the late domain of viral Gag proteins via its central V 
domain (Fisher et al., 2007; Zhai et al., 2008) and is critical for 
ESCRT-III recruitment and viral budding (Usami et al., 2007). 
A search of the PAR1 cytoplasmic domains for such a sequence 
revealed a highly conserved motif within the second intracellular 
loop of the receptor (Fig. 7 A). The PAR1 Y206PMQSL211 motif 
conforms to the ALIX-binding motif YPXnL (with n = 3) and is 
not present in PAR2 cytoplasmic domains (Fig. 7 A). A search of 
several hundred class A GPCRs for such a motif revealed the 
presence of a highly conserved sequence that conforms to the 
YPXnL motif residing in the second intracellular loop of seven 
other mammalian GPCRs (Table 1). Only one class A GPCR 
harbors a conserved YPXnL motif within the cytoplasmic tail 
domain (Table 1). To examine the importance of the YPX3L 
motif in PAR1 degradation, we mutated the critical Y206 to ala-
nine, as analogous Y mutations in YPXnL motifs of viral Gag 
proteins abrogated ALIX interaction and function (Strack et al., 
2003). The PAR1 Y206A mutant expressed at the surface and 
internalized after activation comparable with WT PAR1 (Fig. S5, 
A and B), suggesting that the PAR1 Y206A mutant traffics to 
and from the cell surface normally.
Next, we examined whether the PAR1 YPX3L motif was 
necessary for interaction with ALIX. HeLa cells coexpressing 
FLAG-PAR1 WT or Y206A mutant together with HA-ALIX 
were stimulated with agonist, and coassociation was examined. 
PAR1 WT robustly associated with ALIX after 10 min of agonist 
stimulation, whereas activated PAR1 Y206A mutant interaction 
with ALIX was negligible (Fig. 7 B). PAR2, which lacks a 
YPXnL motif, also failed to bind to HA-ALIX (Fig. S4 C), sug-
gesting that the YPXnL motif is an important determinant for 
ALIX interaction. We also examined whether the ALIX V do-
main is required for association with PAR1. The ALIX central V 
domain binds directly to YPXnL sequences of viral Gag proteins, 
and mutation of the critical phenylalanine to aspartic acid (F676D) 
was shown to disrupt this interaction (Zhai et al., 2008). In con-
trast to PAR1 interaction with WT ALIX, the HA-ALIX F676D 
mutant failed to bind to PAR1 after 10 min of agonist incubation 
(Fig. 7 C). To confirm direct interaction between the PAR1 
YPX3L motif and the ALIX V domain, we performed in vitro 
binding assays using a biotinylated PAR1 ICL2 peptide contain-
ing the YPX3L motif in pull-down experiments with purified 
GST-tagged ALIX. Strikingly, the ALIX V domain showed ro-
bust interaction with the PAR1 YPX3L containing ICL2 peptide 
(Fig. 7 D), whereas neither the ALIX V domain harboring the 
F676D mutant nor the ALIX Bro1 domain bound to the PAR1 
ICL2 peptide (Fig. 7 D). Together, these findings strongly sug-
gest that ALIX can bind directly to the YPX3L motif of PAR1 via 
its central V domain.
Our experiments indicate that the PAR1 YPX3L motif is 
critical for binding to ALIX. Therefore, we tested whether the 
PAR1 YPX3L motif was necessary for agonist-promoted PAR1 
degradation. Incubation with agonist for 60 min caused an 
50% loss of PAR1 protein (Fig. 8 A). In contrast to WT 
remained intact (Fig. 6 C). Together, these findings support a 
function for ALIX in ubiquitin-independent MVB sorting of 
activated PAR1.
To confirm that ALIX is required for PAR1 degradation, 
we performed knockdown rescue experiments in cells cotrans-
fected with two siRNAs targeting endogenous ALIX together 
with FLAG-tagged PAR1 and an siRNA-resistant HA-ALIX 
WT variant. In cells depleted of endogenous ALIX, agonist-
induced degradation of PAR1 was significantly impaired com-
pared with siRNA-treated control cells (Fig. 6 D, lanes 1–4). 
However, coexpression of siRNA-resistant HA-ALIX WT 
restored activated PAR1 degradation in cells lacking endoge-
nous ALIX (Fig. 6 D, lanes 5 and 6). In contrast, agonist failed 
to induce PAR1 degradation in cells depleted of endogenous 
ALIX and expressing an siRNA-resistant HA-ALIX Bro do-
main deletion mutant (Fig. 6 D, lanes 7 and 8). The N-terminal 
Bro domain of ALIX mediates interaction with CHMP4 (Kim 
et al., 2005). These findings suggest that ALIX-mediated 
MVB/lysosomal sorting of PAR1 requires interaction with 
CHMP4 and is a distinct pathway from that used by ubiqui-
tinated GPCRs.
Figure 5. ALIX associates with PAR1 and mediates interaction with 
CHMP4. (A and B) HeLa cells expressing either FLAG-tagged PAR1 WT, 
0K mutant, or PAR2 were stimulated with 100 µM SFLLRN or 100 µM 
SLIGKV for various times at 37°C. Equivalent amounts of cell lysates 
were immunoprecipitated (IP) and examined as described in Fig. 4 B. IB, 
immunoblotting. (C) HeLa cells expressing FLAG-PAR1 were cotransfected 
with HA-CHMP4B and either 100 nM nonspecific (ns) or ALIX-specific 
siRNAs. Equivalent amounts of cell lysates were immunoprecipitated and 
analyzed as described in Fig. 4 B.
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evaluating its sensitivity to proteinase K digestion after activa-
tion and internalization. Proteinase K protection assays have 
been used previously to assess EGFR sorting to ILVs of MVBs 
(Malerød et al., 2007). HeLa cells expressing PAR1 WT or 
PAR1, agonist-stimulated degradation of the PAR1 Y206A 
mutant was significantly inhibited (Fig. 8 A). Next, we exam-
ined whether PAR1 Y206A mutant remained at the limiting 
membrane of MVBs or sorted to an internal compartment by 
Figure 6. ALIX is required for agonist-
induced PAR1 degradation. (A and C) HeLa 
cells expressing FLAG-tagged PAR1 (A), PAR1 
0K mutant, or PAR2 (C) were transfected 
with 100 nM nonspecific (ns) or ALIX-specific 
siRNAs and stimulated with 100 µM SFLLRN 
or 100 µM SLIGKV at 37°C, as indicated. PAR 
degradation was assessed by immunoblotting 
(IB). The data (mean ± SD) are expressed as 
the fraction of PAR1 remaining compared with 
untreated control (Ctrl) and were analyzed by a 
two-way analysis of variance (*, P < 0.05; n = 3). 
(B) Human endothelial cells transfected with 
100 nM of nonspecific or ALIX-specific siRNAs 
stimulated with 100 µM TFLLRNPNDK at 37°C, 
as indicated, and immunoprecipitated (IP) with 
anti-PAR1 or IgG antibodies (Ab). Endogenous 
PAR1 was detected by immunoblotting. Cell 
lysates were immunoblotted with anti-ALIX 
and -actin antibodies. The data (mean ± SD) are 
expressed as a fraction of untreated control and 
were analyzed by a two-way analysis of vari-
ance (*, P < 0.05; n = 3). (D) HEK293 cells 
cotransfected with either 100 nM of nonspecific 
or two ALIX-specific siRNAs together with FLAG-
PAR1 and either siRNA-resistant HA-ALIX WT or 
HA-ALIX Bro1 were incubated with or without 
100 µM SFLLRN for 50 min at 37°C. Equivalent 
amounts of lysates were analyzed for PAR1, en-
dogenous ALIX (lanes 1–4), HA-ALIX WT (lanes 
5 and 6), or HA-ALIX Bro1 (lanes 7 and 8) 
expression by immunoblotting.
Figure 7. A YPX3L motif of PAR1 mediates bind-
ing to ALIX. (A) Alignment of PAR1 and PAR2 ICL2 
sequences from various species. The conserved 
residues of the YPX3L motif are shaded in gray. 
(B) HeLa cells coexpressing HA-ALIX WT and either 
FLAG-PAR1 WT or Y206A mutant were stimulated 
with 100 µM SFLLRN at 37°C, as indicated. Cell 
lysates were immunoprecipitated and examined 
as described in Fig. 4 B. IB, immunoblotting. The 
data (mean ± SD) represent the amount of immuno-
precipitated ALIX normalized to the amount of 
immunoprecipitated PAR1 and were significant, 
as determined by Student’s t test (**, P < 0.01; 
n = 3). A.U., arbitrary unit. (C) HeLa cells trans-
fected with FLAG-PAR1 and either HA-ALIX WT or 
F676D mutant were stimulated with agonist and 
processed as previously described. Cell lysates 
were immunoblotted with anti-HA and -actin anti-
bodies. The data (mean ± SD) were calculated, 
as previously described, and significant, as deter-
mined by Student’s t test (**, P < 0.01; n = 3). 
(D) Biotinylated PAR1 ICL2 peptide containing 
the YPX3L motif was immobilized on streptavidin 
beads and incubated with GST, GST–ALIX V do-
main, GST–ALIX V F676D, or the GST–ALIX Bro1 
domain. Pulldowns (PD) were analyzed for the 
presence of bound protein by immunoblotting. Input 
was analyzed by Coomassie staining.
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were efficiently degraded after exposure to proteinase K in sam-
ples supplemented by Triton X-100, which allows proteinase K 
access to internal membranous compartments (Fig. 8 B, lanes 3, 6, 
9, and 12). The early endosomal antigen protein 1 (EEA1) was also 
efficiently degraded in all proteinase K–treated samples, demon-
strating effective plasma membrane permeabilization and pro-
teinase K activity (Fig. 8 B). In addition, the PAR1 Y206A 
mutant internalized to EEA1-positive endosomes like WT re-
ceptor in cells treated with agonist for 10 min (Fig. 8 C), and 
both sorted from the EEA1-containing endosomes after 20 min 
(Fig. 8 C). The extent of colocalization with EEA1 at 10 min was 
quantified by determining the Pearson’s correlation coefficient for 
PAR1 WT (r = 0.50 ± 0.1; n = 6) and Y206A (r = 0.43 ± 0.09; 
Y206A mutant were incubated with agonist for 15 min at 37°C, 
washed, and gently permeabilized with digitonin. Membranes 
were isolated, divided into aliquots, and either left untreated, 
treated with proteinase K, or treated with proteinase K supple-
mented with 0.1% Triton X-100. Activation of PAR1 WT 
resulted in a greater accumulation of receptor in proteinase K–
treated samples compared with unstimulated control samples 
(Fig. 8 B, lanes 2 and 5), indicating that activated PAR1 WT is 
sorted into protective endosomal compartments. In contrast, 
PAR1 Y206A mutant failed to accumulate in protective endosomal 
compartments compared with unstimulated control (Fig. 8 B, 
lanes 8 and 11), suggesting the PAR1 Y206A mutant is defective 
in MVB sorting. However, both PAR1 WT and Y206A mutant 
Table 1. Human GPCRs with conserved YPXnL motifs
Family IUPHAR nomenclature NCBI Protein database  
accession no.
YPXnL location Sequence
Adrenoceptors 1B Adrenoceptor P35368 ICL2 141-DRYIGRYSLQYPTLVT-158
Angiotensin AT2 P50052 ICL2 140-DRYQSVIYPFLSQRRN-157
Galanin GAL2 O43603 ICL2 121-DRYLAIRYPLHSRELRT-139
Histamine H2 P25021 ICL2 114-DRYCAVMDPLRYPVLVT-132
Neuropeptide FF NPFF2 A0PJM9 ICL2 141-DRFQCVVYPFKPKLTIK-159
Neuropeptide S NPS receptor Q6W5P4 ICL2 144-DRYHAIVYPMKFLQGE-161
Protease activated PAR1 P25116 ICL2 198-DRFLAVVYPMQSLSWRT-216
P2Y P2Y1 P47900 ICL2 147-HRYSGVVYPLKSLGRLK-165
Melanocortin MC4 P32245 Cytoplasmic tail 318-YPLGGLCDLSSRY-stop
A search of 397 class A GPCR cytoplasmic sequences for YPXnL motifs was completed by sequence alignment using the GPCR database (Vroling et al., 2011). Of 
these, several GPCRs contained sequences conforming to the YPXnL motif in the ICL2 (bold) and were aligned starting with the DRY/F motif. The list includes the GPCR 
family name, International Union of Basic and Clinical Pharmacology (IUPHAR) nomenclature, and NCBI accession numbers.
Figure 8. The YPX3L motif of PAR1 is essential for 
MVB/lysosomal sorting. (A) HeLa cells expressing 
FLAG-PAR1 WT or Y206A mutant were incubated 
with 100 µM SFLLRN at 37°C, as indicated. PAR1 
degradation was analyzed as described in Fig. 2 B. 
IB, immunoblotting. The data (mean ± SD) are 
expressed as a fraction of untreated control (Ctrl) 
and were analyzed by a two-way analysis of 
variance (*, P < 0.05; ***, P < 0.001; n = 3). 
(B) HeLa cells expressing FLAG-PAR1 WT or Y206A 
were untreated (control) or treated with 100 µM 
SFLLRN (SF) for 15 min at 37°C. Membranes were 
isolated and treated with proteinase K or protein-
ase K with 0.1% Triton X-100, and PAR1 or EEA1 
was detected by immunoblotting. The data (mean ± 
SD) are expressed as the fraction of PAR1 re-
maining after proteinase K treatment compared 
with untreated control () from either the control or 
SFLLRN (+SF)-treated samples and were analyzed 
by Student’s t test (*, P < 0.05; n = 3). (C and D) 
HeLa cells expressing either FLAG-PAR1 WT or 
Y206A mutant were prelabeled with anti-FLAG anti-
body at 4°C and incubated with 100 µM SFLLRN 
at 37°C, as indicated. Cells were immunostained 
for either EEA1 or LAMP1 and analyzed, as de-
scribed in Fig. 1 A. Insets show magnifications of 
boxed areas. Bars, 10 µm. The data (mean ± SD) 
represent Pearson’s correlation coefficients that 
were calculated, as described in Fig. 1 A, and 
were analyzed by Student’s t test (**, P < 0.01; 
***, P < 0.001; n = 6).
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subunits, suggesting that ubiquitin binding is not essential for 
ESCRT-III–mediated PAR1 degradation. Moreover, ubiquitina-
tion is not a prerequisite for cargo passage into ILVs, as ESCRT-III 
subunits recruit enzymes that appear to deubiquitinate cargo 
before ILV entry (Kyuuma et al., 2007). Thus, unlike most 
cargo sorted to ILVs of MVBs via the canonical ESCRT pathway, 
our findings indicate that PAR1 is uniquely sorted by ESCRT-III 
independent of ubiquitination. This pathway is also distinct 
from the entirely ESCRT-independent ILV sorting pathway pre-
viously described for the melanosome constituent Pmel and the 
proteolipid protein (Theos et al., 2006; Trajkovic et al., 2008; 
van Niel et al., 2011). Other cargo, such as the yeast Sna3 and 
mammalian DOR, are also not directly ubiquitinated, but certain 
ubiquitin-binding ESCRT components facilitate MVB/lysosomal 
sorting (Hislop et al., 2004; McNatt et al., 2007; Oestreich et al., 
2007; Watson and Bonifacino, 2007).
Our findings also reveal a novel function for ALIX, a 
CHMP4–ESCRT-III interacting protein, in mediating MVB/ 
lysosomal sorting of PAR1. ALIX directly binds to and recruits 
CHMP4–ESCRT-III to membranes via interaction with its Bro 
domain and is important for abscission during cytokinesis and 
budding of certain viruses (Strack et al., 2003; Morita et al., 
2007). However, ALIX function in cargo sorting at MVBs in 
mammalian cells is not known. Bro1, the yeast homolog of 
ALIX, facilitates the sorting of ubiquitinated cargo at MVBs 
(Odorizzi et al., 2003). In yeast, Bro1 recruits the deubiquitinat-
ing enzyme Doa4 to the late endosome, which is essential for 
cargo deubiquitination and sorting at the MVB. However, in 
mammalian cells, ALIX does not appear to function in lyso-
somal sorting of ubiquitinated cargo, as depletion of ALIX by 
siRNA failed to affect degradation of EGFR (Cabezas et al., 
2005), a receptor that requires direct ubiquitination and ESCRTs 
for degradation. We found that the association of ALIX with ac-
tivated PAR1 coincided with PAR1 sorting to ILVs at the MVB. 
Moreover, degradation of endogenous and ectopically expressed 
PAR1 was significantly impaired in ALIX-deficient cells and 
was restored by expression of an siRNA-resistant ALIX WT 
variant, indicating that ALIX function is specific for this path-
way. ALIX also mediated degradation of ubiquitination-deficient 
PAR1, but not the related PAR2, which requires ubiquitination 
for lysosomal sorting. In addition, ALIX is required for activated 
PAR1 recruitment of CHMP4 subunits, the critical components 
of ESCRT-III, and the ALIX Bro domain important for CHMP4 
interaction is necessary for the rescue of agonist-promoted PAR1 
degradation in cells deficient in endogenous ALIX expression. 
Thus, ALIX has the capacity to mediate cargo sorting at the 
MVB in mammalian cells through a pathway that requires 
ESCRT-III recruitment. ALIX-mediated MVB sorting of PAR1 
also appears to be distinctly regulated, as PAR1 does not accu-
mulate at MVBs when ILV sorting is blocked, compared with 
ubiquitinated cargo that use canonical ESCRT components. The 
mechanistic basis for this observation is not known but may in-
volve trafficking of PAR1 from the MVB to a different compart-
ment and/or recycling back to the cell surface.
This study is the first to demonstrate ALIX-mediated 
MVB/lysosomal sorting of a mammalian cell host protein via a 
YPXnL motif. The ALIX central V domain has been shown to 
n = 6). Interestingly, however, PAR1 Y206A mutant showed 
minimal colocalization with LAMP1 after 20 min of agonist 
stimulation compared with WT PAR1 (Fig. 8 D), which was 
verified by Pearson’s correlation coefficient for PAR1 WT (r = 
0.28 ± 0.08; n = 6) and Y206A (r = 0.08 ± 0.02; n = 6). Thus, 
the YPX3L motif is a critical determinant for PAR1 ubiquitin–
independent MVB/lysosomal sorting (Fig. 9).
Discussion
In this study, we define a new ubiquitin-independent MVB/
lysosomal sorting pathway for signaling receptors that requires 
ALIX and ESCRT-III function in mammalian cells. We demon-
strate that activated PAR1 is sorted to ILVs of MVBs indepen-
dent of receptor ubiquitination but requires ESCRT-III function. 
Our data further indicate that PAR1 degradation is regulated by 
ALIX, which binds directly to a YPX3L motif localized within 
the PAR1’s intracellular loop via its central V domain and me-
diates CHMP4/ESCRT-III recruitment to the receptor. Thus, 
PAR1 bypasses the requirement for ubiquitination and ubiquitin-
binding ESCRTs but requires ALIX and ESCRT-III for sorting 
to ILVs of MVBs (Fig. 9).
We previously showed that lysosomal sorting of PAR1 
occurs independent of ubiquitination and the ubiquitin-binding 
ESCRT components HRS and Tsg101 (Gullapalli et al., 2006; 
Wolfe et al., 2007), but whether PAR1 sorts to ILVs of MVBs 
remained unknown. Here, we show that a ubiquitination-deficient 
PAR1 mutant sorted to ILVs similar to WT receptor, indicating 
that ubiquitination is not essential for ILV sorting of PAR1. Our 
experiments further indicate that CHMP4, the major subunit of 
ESCRT-III and driver of ILV scission, is essential for agonist-
induced PAR1 degradation. In contrast to other ESCRT com-
plexes, ESCRT-III does not contain any known ubiquitin-binding 
Figure 9. GPCR ubiquitin-dependent and -independent MVB sorting. The 
ubiquitin-mediated MVB sorting pathway of PAR2 requires the ESCRT-0, 
-I, and -II complexes before ESCRT-III–mediated incorporation into ILVs. In 
contrast, PAR1 MVB sorting is mediated by ALIX recruitment of the ESCRT-III 
complex, independent of ubiquitination (Ub).
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to HRP was purchased from Roche. HRP-conjugated goat–anti rabbit and 
goat–anti mouse antibodies were purchased from Bio-Rad Laboratories. 
Alexa Fluor 488, 594, and 647 secondary antibodies were purchased 
from Invitrogen.
Plasmids and cell lines
The full-length human N-terminal FLAG-tagged PAR1 WT, FLAG-PAR1 0K 
mutant cDNAs cloned into the mammalian expression vector pBJ, and full-
length FLAG-tagged PAR2 cloned into pBJ vector were previously described 
(Trejo et al., 2000; Wolfe et al., 2007; Ricks and Trejo, 2009). The FLAG-
PAR1 Y206A mutant cloned into pBJ vector was generated by QuikChange 
mutagenesis (Agilent Technologies) and confirmed by dideoxy sequenc-
ing. The full-length FLAG-tagged 2AR cloned into pcDNA3.1 was pro-
vided by M. von Zastrow (University of California San Francisco, San 
Francisco, CA). The GFP-tagged Vps4 WT and E228Q mutants were 
cloned into pEGFP vector and provided by A. Marchese (Loyola University, 
Maywood, IL). FLAG-tagged CHMP4A construct was provided by P. Hanson 
(Washington University, St. Louis, MO). The cDNAs encoding HA-CHMP4B, 
HA-CHMP4C, HA-ALIX WT, and HA-ALIX F676D and Bro domain mutants 
were provided by J. Martin-Serrano (King’s College, London, England, 
UK). GST–ALIX V, ALIX V F676D, and ALIX Bro1 constructs were provided 
by W. Sundquist (University of Utah, Salt Lake City, UT). HeLa cells stably 
expressing FLAG-PAR1 or FLAG-PAR2 cloned into pBJ vectors under the 
control of cytomegalovirus promoter were generated by cotransfection with 
a plasmid encoding a hygromycin resistance gene, selected in 250 µg/ml 
hygromycin, and screened by cell surface ELISA. Cells were grown and 
maintained as previously described (Trejo et al., 2000). Human endothe-
lial EA.hy926 cells were grown and maintained as previously described 
(Russo et al., 2009).
siRNA and cDNA transfections
HeLa cells or endothelial cells were transfected with 100 nM siRNA using 
either Lipofectamine 2000 (Invitrogen) or Oligofectamine (Invitrogen), 
respectively, and examined after 48 h. The CHMP4A, CHMP4B, CHMP4C, 
Vps4A, Vps4B, and ALIX siRNAs were purchased as SMARTpools from 
Thermo Fisher Scientific. The single CHMP4B siRNAs used were 1 (5-AGAA-
GAGUUUGACGAGGAU-3) and 2 (5-CGGAAGAGAUGUUAACGAA-3). 
Nonspecific siRNA (5-GGCUACGUCCAGGAGCGCACC-3) was used 
as a negative control. The ALIX knockdown rescue experiment was per-
formed by cotransfecting HEK293 cells with ALIX-specific siRNAs (5-GUA-
CCUCAGUCUAUAUUGA-3 and 5-UCGAGACGCUCCUGAGAUA-3; 
Thermo Fisher Scientific) together with cDNAs containing HA-ALIX WT or 
HA-ALIX Bro domain mutant harboring silent mutations within the siRNA-
targeted region using Lipofectamine 2000 reagent.
Immuno-EM
HeLa cells stably expressing full-length FLAG-PAR1 or FLAG PAR1 0K 
mutant were grown in 10-cm dishes (1.0 × 106 cells/dish) for 48 h. Cells 
were washed and preincubated on ice for 1 h with anti-FLAG antibody to 
label only receptors at the cell surface. Cells were washed to remove un-
bound antibody and treated with agonist for 20 min at 37°C, fixed with 
4% PFA in 0.1 M phosphate buffer, pH 7.4, overnight at room tempera-
ture, washed with 0.15 M glycine/phosphate buffer, and then embedded 
in 10% gelatin/phosphate buffer infused with 2.3 M sucrose/phosphate 
buffer overnight at 4°C. 1-mm3 cell blocks were mounted onto specimen 
holders and snap frozen in liquid nitrogen. Ultracryomicrotomy was per-
formed at 100°C on an ultramicrotome with an EM FCS cryoattachment 
(Ultracut UCT; Leica) using a diamond knife (DiATOME US). 80–90-nm 
frozen sections were picked up with a 1:1 mixture of 2.3 M sucrose and 
2% methyl cellulose, as previously described (Lavoie et al., 2002), and 
transferred onto Formvar and carbon-coated copper grids. Immunolabel-
ing was performed by placing grids on 2% gelatin at 37°C for 20 min and 
rinsed with 0.15 M glycine/PBS, and the sections were blocked using 1% 
cold water fish skin gelatin. Previously titrated primary antibodies were di-
luted in 1% BSA/PBS. Incubation with primary antibodies for 1 h at room 
temperature was followed by gold-conjugated goat anti–mouse IgG and 
IgM (Jackson ImmunoResearch Laboratories, Inc.) or gold-conjugated goat 
anti–rabbit IgG, both diluted 1/25 in 1% BSA/PBS at room temperature 
for 30 min. Grids were viewed using a transmission electron microscope 
(1200-EX II; JEOL) and photographed using a digital camera (Gatan, Inc) 
at the University of California San Diego Electron Microscopy Facility.
PAR degradation assay
HeLa cells stably expressing FLAG-PAR1, FLAG-PAR1 0K, or FLAG-PAR2 
were plated in 12-well dishes (1.5 × 105 cells/well) and grown overnight 
bind to YPXnL motifs of retroviral Gag proteins (Fisher et al., 
2007; Zhai et al., 2008). We found that ALIX directly interacts 
with a highly conserved YPX3L motif within the PAR1’s intra-
cellular loop via its V domain to facilitate MVB/lysosomal deg-
radation. Previous studies showed that the HIV-1 and EIAV 
viruses recruit the ESCRT machinery through interaction with 
ALIX (Strack et al., 2003; Zhai et al., 2008) The HIV-1 struc-
tural Gag protein harbors a tetrapeptide motif that binds to 
Tsg101 (Garrus et al., 2001; Martin-Serrano et al., 2001) and a 
YPXnL motif that interacts with the V domain of ALIX (Strack 
et al., 2003; Fisher et al., 2007) to mediate ESCRT-III recruit-
ment. In contrast, EIAV Gag proteins only possess an ALIX-
binding YPXnL motif that is critical for ESCRT-III recruitment 
(Martin-Serrano et al., 2003) and viral budding (Tanzi et al., 
2003). Similar to HIV-1 and EIAV (Strack et al., 2003), muta-
tion of the critical tyrosine within the YPX3L motif of PAR1 
disrupted interaction with ALIX and impaired PAR1 MVB/
lysosomal degradation. In vitro binding assays confirmed that the 
V domain of ALIX binds directly to the YPX3L motif of PAR1. 
Thus, ALIX directly interacts with PAR1 and mediates MVB/
lysosomal sorting via an ESCRT-III–dependent pathway.
In summary, this study provides the first molecular insight 
into a mechanism by which a signaling receptor can sort to 
ILVs of MVBs independent of ubiquitination and ubiquitin-
binding ESCRTs. Unlike most ubiquitinated cargo, we show 
that PAR1 sorts to ILVs of MVBs through a distinct ubiquitin-
independent pathway that requires ALIX and ESCRT-III func-
tion but not the canonical ubiquitin-binding ESCRT components. 
These findings unveil a new mechanism that enriches the diver-
sity of MVB sorting pathways for signaling receptors. This 
work also suggests that ubiquitination of mammalian GPCRs is 
likely to have additional functions besides mediating receptor 
sorting at the MVB. ALIX has also been shown to bind to the 
cytoplasmic tail domains of the transferrin receptor (Géminard 
et al., 2004), the GPCR vasopressin V2R (Yi et al., 2007), and 
D1-like and D3 dopamine GPCRs (Zhan et al., 2008) and ap-
pears to regulate various aspects of receptor trafficking. How-
ever, these cargo lack the ALIX-binding YPXnL motif, and, 
thus, mechanistically how ALIX functions in these pathways is 
not known. Remarkably, we discovered seven other mamma-
lian GPCRs that contained conserved YPXnL motifs within 
their second intracellular loop, raising the intriguing possibility 
that ALIX mediates MVB/lysosomal sorting of a subset of 
GPCRs in mammalian cells.
Materials and methods
Antibodies and reagents
PAR1 peptide agonists (SFLLRN and TFLLRNPNDK) and PAR2 peptide ag-
onist (SLIGKV) were synthesized and purified by reverse-phase high-pressure 
liquid chromatography at the Tufts University Core Facility. Polyclonal 
anti-FLAG and -HA antibodies were obtained from Rockland Immuno-
chemicals. Anti-LAMP1 and -CD63 antibodies were obtained from the 
Developmental Studies Hybridoma Bank. Anti-EEA1 antibody was ob-
tained from BD. Monoclonal anti-PAR1 WEDE antibody was purchased 
from Beckman Coulter. Polyclonal CHMP4A and CHMP4B antibodies as 
well as monoclonal anti-ALIX (3A9) and anti-Vps4 antibodies were ob-
tained from Santa Cruz Biotechnology, Inc. The monoclonal anti-HA and -GFP 
antibodies were purchased from Covance. The M2 anti-FLAG and -actin anti-
bodies were obtained from Sigma-Aldrich. The HA antibody conjugated 
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guttata (NCBI Protein database accession no. XP_002189106.1), Danio 
rerio (GenBank accession no. CAM13317.1), and Homo sapiens PAR1 
(GenBank accession no. AAA36743.1) and PAR2 (GenBank accession 
no. AAP97012.1). Sequences were aligned using ClustalX 2.1 software 
(Larkin et al., 2007).
In vitro binding assay
A biotinylated PAR1 ICL2 peptide representing the second intracellular 
loop sequence LAVVYPMQSLSWRTLG (the segment in italics denotes the 
YPXL motif within the peptide fragment, which is required for binding to 
ALIX in the context of full-length PAR1) was synthesized and purified by the 
Tufts University Core Facility. Biotinylated PAR1 ICL2 peptide was immobi-
lized on streptavidin beads (Sigma-Aldrich). GST vector, GST–ALIX V, 
GST–ALIX V F676D, and GST-ALIX Bro1 cDNA plasmids were transformed 
into BL21 (DE3) Escherichia coli cells (Agilent Technologies). E. coli were 
grown in ZYP-5052 media (1% tryptone, 0.5% yeast extract, 0.025 M 
(NH4)2SO4, 0.05 M KH2PO4, 0.05 M Na2HPO4, 0.5% glycerol, 0.05% 
glucose, and 0.2% -lactose) and lysed, and GST fusion proteins were pu-
rified on GST resin (EMD). GST fusion proteins were eluted, and protein 
concentrations were determined using BCA assay and GST fusion proteins 
(10 µg) and then incubated with immobilized biotinylated PAR1 ICL2 pep-
tide for 1 h at 4°C. After washing, samples were eluted in 2× sample buf-
fer resolved by SDS-PAGE and analyzed by immunoblotting to detect 
GST–ALIX association. The input, 25%, was run on an SDS-PAGE gel and 
stained with Coomassie to visualize proteins.
Proteinase K protection assay
The proteinase K protection assay was performed as previously described 
(Malerød et al., 2007), with minor modifications. HeLa cells were plated 
in six-well culture dishes (4.0 × 105 cells/well), grown overnight at 37°C, 
and treated with or without agonist. Cells were placed on ice and incubated 
for 5 min with PBS, harvested, and gently permeabilized using 6.5 µg/ml dig-
itonin. Membranes were collected by centrifugation and resuspended in 
buffer (100 mM K2HPO4/KH2PO4, 5 mM MgCl2, and 250 mM sucrose). 
Membranes were then divided into three aliquots either left untreated, 
treated with 2.5 ng/ml proteinase K, or treated with proteinase K supple-
mented with 0.1% Triton X-100 for 10 min at room temperature. After 
treatments, samples were diluted with 100 µl of 2× SDS sample buffer con-
taining 20 mM PMSF and analyzed by immunoblotting.
RT-PCR
The first-strand cDNA was generated from mRNA extracted from either 
HeLa using SuperScript II reverse transcription (Invitrogen) following the man-
ufacturer’s instructions. The RT enzyme was omitted from the cDNA synthe-
sis reaction in the control samples. The first-strand cDNA was amplified 
via PCR using primer pairs specific for CHMP4A (forward 5-GCAT-
GAAGAAGGCCTACCAG-3 and reverse 5-AGGCAGGGTCACACT-
ACCAC-3), CHMP4B (forward 5-CCCATGACAACATGGACATC-3 
and reverse 5-AGCCCAGTTCTCCAATTCCT-3), or CHMP4C (forward 
5-GAACTCCACAGCAATGAGCA-3 and reverse 5-AGTCATCACCA-
AAGCCAACC-3). The PCR amplification products were resolved by 
1.8% (wt/vol) agarose gel electrophoresis and visualized by ethidium 
bromide staining.
Cell surface ELISA
HeLa cells were plated at 0.5 × 105 cells/well in a 24-well culture dish, 
grown overnight, and transfected, as previously described. After 48 h, 
cells were either left untreated or treated with 100 µM SFLLRN (PAR1-specific 
agonist) for varying times at 37°C, and the amount of receptor remain-
ing at the cell surface was determined, as previously described (Soto and 
Trejo, 2010). In brief, cells were fixed in 4% PFA, washed, and then incu-
bated with polyclonal anti-FLAG antibody followed by secondary HRP-
conjugated goat anti–rabbit antibody. The amount of antibody bound 
to the cell surface was determined by incubation with one-step 2,2’-
azinobis-3-ethylbenzthiazoline-6-sulfonic acid (Thermo Fisher Scientific) 
substrate for 10–20 min at room temperature. An aliquot was removed, 
and the absorbance at 405 nm was determined using a microplate reader 
(SpectraMax Plus; Molecular Devices).
Statistics
Data were analyzed using Prism software (version 4.0; GraphPad Soft-
ware). Statistical analysis was determined, as indicated, by performing 
either Student’s t test or two-way analysis of variance.
Online supplemental material
Fig. S1 shows the localization of PAR1 WT and 0K mutant at steady state 
and after stimulation with agonist for 60 min, relative to EEA1-positive 
at 37°C and transfected with either siRNAs or cDNA plasmids. After 48 h, 
cells were washed and treated with or without 100 µM SFLLRN (PAR1-
specific agonist) or 100 µM SLIGKV (PAR2-specific agonist) for various 
times at 37°C. Cells were placed on ice, washed with PBS, and lysed in 
Triton X-100 lysis buffer (50 mM Tris-HCl, pH 7.4, 100 mM NaCl, 5 mM 
EDTA, 50 mM NaF, 10 mM NaPP, and 1% Triton X-100) supplemented 
with protease inhibitors. Cell lysates were collected and sonicated for 10 s 
at 10% amplitude (model 450 sonifier; Branson), and protein concentra-
tions were determined by bicinchoninic acid (BCA) assay (Thermo Fisher 
Scientific). Equivalent amounts of lysates were used for analysis by immuno-
blotting. Endothelial cells were plated in 6-cm dishes (3.0 × 106 cells/
plate), grown for 2 d, stimulated with 100 µM TFLLRNPNDK (PAR1-specific 
agonist) for various times at 37°C, and lysed with radioimmunoprecipi-
tation assay lysis buffer (5 mM EDTA, 50 mM Tris-HCl, 150 mM NaCl, 
0.5% [wt/vol] Na-deoxycholate, 1% [volume/volume] NP-40, and 0.1% 
[wt/vol] SDS) supplemented with protease inhibitors, and equivalent 
amounts of lysates were immunoprecipitated using the anti-PAR1 WEDE 
antibody. PAR1 degradation was assessed as previously described (Russo 
et al., 2009).
Coimmunoprecipitation assay
HeLa cells stably expressing FLAG-PAR1 were grown in six-well plates (4.0 × 
105 cells/well) overnight and transiently transfected with either HA-CHMP4 
or HA-ALIX. Alternatively, HeLa cells plated in six-well dishes were transiently 
cotransfected with PAR1 WT or Y206A mutant together with HA-ALIX. After 
48 h, cells were treated with 100 µM SFLLRN (PAR1-specific agonist) for vary-
ing times at 37°C, washed, and lysed with 0.5% NP-40 lysis buffer contain-
ing 20 mM Tris-HCl, pH 7.4, and 150 mM NaCl. Cell lysates were sonicated 
and cleared by centrifugation, and equivalent amounts of lysates determined 
by BCA assay were precleared with protein A Sepharose CL-4B for 1 h at 
4°C. Precleared lysates were then immunoprecipitated with M2 anti-FLAG 
antibody or IgG overnight at 4°C. Immunoprecipitates were washed, resus-
pended in 2× sample buffer, resolved by SDS-PAGE, transferred to mem-
branes, and examined by immunoblotting. For PAR1 coimmunoprecipitation 
of endogenous CHMP4 and ALIX, HeLa cells expressing FLAG-PAR1 WT or 
FLAG-PAR1 0K mutant were grown in six-well plates (4.0 × 105 cells/well). 
After 48 h, cells were treated with agonist and lysed in buffer, as previously 
stated. Equivalent amounts of lysates were then immunoprecipitated with anti-
PAR1 or polyclonal anti-FLAG antibodies, and the coassociation of CHMP4 
or ALIX in immunoprecipitates was examined by immunoblotting.
Immunofluorescence confocal microscopy
HeLa cells stably expressing FLAG-PAR1 or FLAG-PAR2 were plated on 
coverslips in 12-well dishes and grown overnight. Cells were washed, stim-
ulated with agonists, 100 µM SFLLRN (PAR1 specific), or 100 µM SLIGKV 
(PAR2 specific) for various times at 37°C, fixed in 4% PFA, permeabilized 
in 100% methanol, and processed for microscopy, as previously described 
(Trejo et al., 2000). Cells were then immunostained with an anti-FLAG 
polyclonal rabbit antibody to detect either PAR1 or PAR2 followed by 
monoclonal anti-EEA1, -LAMP1, or -CD63 antibodies and then incubated 
with species-specific secondary antibodies conjugated to Alexa Fluors and 
imaged by confocal microscopy. To specifically track activated PAR1 or 
PAR2 from the cell surface, cells were prelabeled with anti-FLAG antibody 
for 1 h at 4°C to ensure only surface FLAG-PAR1 or FLAG-PAR2–bound anti-
body, stimulated with agonist for various times at 37°C, and then pro-
cessed for microscopy. Fixed cells were mounted in FluorSave reagent 
(EMD). The fluorochromes used were Alexa Fluor 488, 594, and 647 and 
GFP. Images were acquired with a disk-spinning unit confocal system 
(Olympus) configured with a microscope (IX81; Olympus) fitted with a 
PlanApo 60× oil objective (1.4 NA; Olympus) and a digital camera (ORCA-
ER; Hamamatsu Photonics). Fluorescent images of 0.28-µm-thick X–Y 
sections were acquired at room temperature using SlideBook software (ver-
sion 4.2; Intelligent Imaging Innovations, Inc.). Pearson’s correlation coeffi-
cients for quantifying colocalization of PAR1 WT and mutants with either 
EEA1 or LAMP1 were calculated for six independent cells from multiple ex-
periments using SlideBook software (version 4.2).
Protein sequence alignment
The following protein sequences were acquired from the National Center 
for Biotechnology Information protein database: Rattus norvegicus (avail-
able from GenBank under accession no. AAA42274.1), Xenopus laevis 
(GenBank accession no. AAA18498.1), Mus musculus (GenBank accession 
no. AAA40438.1), Papio hamadryas (GenBank accession no. AAB84191.1), 
Cricetulus longicaudatus (GenBank accession no. AAA86747.1), Bos taurus 
(NCBI Protein database accession no. NP_001096567.1), Equus caballus 
(NCBI Protein database accession no. XP_001504007.2), Taeniopygia 
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